Literature DB >> 16130510

Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients.

A Selva-O'Callaghan1, M Labrador-Horrillo, X Muñoz-Gall, X Martínez-Gomez, J Majó-Masferrer, R Solans-Laque, C P Simeon-Aznar, F Morell-Brotard, M Vilardell-Tarrés.   

Abstract

The objective of this study was to assess the prevalence, clinical, histological and immunological characteristics, and the long-term outcome of polymyositis- (PM) and dermatomyositis- (DM) associated lung disease, and to define subgroups of lung-associated inflammatory myopathies. This retrospective study included 81 consecutive patients diagnosed with PM/DM. Pulmonary involvement was systematically investigated in relation to clinical symptoms by chest radiography, high resolution computed tomography and pulmonary function testing. Anti-synthetase autoantibodies (ASA) were analysed by ELISA and confirmed by protein and RNA immunoprecipitation methods. Statistical analyses were done with the Student t-test and Fisher exact test. Cumulative survival probabilities were estimated by the Kaplan-Meier method and Cox regression analysis. Fifty patients (61%) presented pulmonary involvement. Thirty-two (39%) had interstitial lung disease and five of them had devastating acute interstitial pneumonia with pneumomediastinum and an unfavorable prognosis. Histology showed diffuse alveolar damage in this subgroup and ASA were negative. Eighteen patients (22%) presented restrictive myopathic lung disease; in three of them respiratory muscles could not maintain ventilation. ASA were positive in 17 of the 50 patients (34%) and were significantly associated with interstitial lung disease (OR: 4.5 [95% CI: 1.3-15.3]), arthritis (OR: 6.0 [95% CI: 1.3-29.2]) and 'mechanic hands' (OR: 8.5 [95% CI: 1.7-41.4]); the presence of these autoantibodies did not imply worse survival prognosis. We concluded that clinical and immunological characteristics allowed the grouping of patients into different types of PM/DM lung-associated disease. Presence of ASA did not affect survival. ASA-negative patients with acute interstitial pneumonitis and pneumomediastinum had an unfavorable prognosis.

Entities:  

Mesh:

Year:  2005        PMID: 16130510     DOI: 10.1191/0961203305lu2158oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  24 in total

1.  Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Authors:  Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis
Journal:  Curr Rheumatol Rev       Date:  2010-05

2.  Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations.

Authors:  Pamela A Morganroth; Mary Elizabeth Kreider; Joyce Okawa; Lynne Taylor; Victoria P Werth
Journal:  Arch Dermatol       Date:  2010-07

3.  Successful use of extracorporeal membrane oxygenation for severe interstitial lung disease in a child with dermatomyositis.

Authors:  Francesco Zulian; Maria Martha Martinez Toledo; Angela Amigoni; Giorgia Martini; Caterina Agosto; Andrea Pettenazzo
Journal:  Intensive Care Med       Date:  2007-06-27       Impact factor: 17.440

4.  Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases.

Authors:  Kuang-Hui Yu; Yeong-Jian Jan Wu; Chang-Fu Kuo; Lai-Chu See; Yu-Ming Shen; Hsiao-Chun Chang; Shue-Fen Luo; Huei-Huang Ho; I-Jung Chen
Journal:  Clin Rheumatol       Date:  2011-09-14       Impact factor: 2.980

5.  Living-donor lobar lung transplantation for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis: report of a case.

Authors:  Tsuyoshi Shoji; Toru Bando; Takuji Fujinaga; Fengshi Chen; Hajime Sasano; Naoichiro Yukawa; Tsuneyo Mimori; Hiroshi Date
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-05-23

6.  Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis.

Authors:  M O Harris-Love; J A Shrader; D Koziol; N Pahlajani; M Jain; M Smith; H L Cintas; C L McGarvey; L James-Newton; A Pokrovnichka; B Moini; I Cabalar; D J Lovell; R Wesley; P H Plotz; F W Miller; J E Hicks; L G Rider
Journal:  Rheumatology (Oxford)       Date:  2008-12-11       Impact factor: 7.580

7.  Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients.

Authors:  Rohit Aggarwal; Elaine Cassidy; Noreen Fertig; Diane Carol Koontz; Mary Lucas; Dana P Ascherman; Chester V Oddis
Journal:  Ann Rheum Dis       Date:  2013-02-19       Impact factor: 19.103

8.  Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up.

Authors:  K P Ng; F Ramos; S M Sultan; D A Isenberg
Journal:  Clin Rheumatol       Date:  2009-04-23       Impact factor: 2.980

9.  Connective Tissue Disease-associated Interstitial Lung Disease: A review.

Authors:  Markus Gutsche; Glenn D Rosen; Jeffrey J Swigris
Journal:  Curr Respir Care Rep       Date:  2012-09-21

Review 10.  Pneumomediastinum in dermatomyositis itself is not a poor prognostic factor: report of a case and review of the literature.

Authors:  Ken Yoshida; Daitaro Kurosaka; Isamu Kingetsu; Kenichiro Hirai; Akio Yamada
Journal:  Rheumatol Int       Date:  2008-02-29       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.